No Association between the Plasmodium vivax crt-o MS334 or In9 pvcrt Polymorphisms and Chloroquine Failure in a Pre-Elimination Clinical Cohort from Malaysia with a Large Clonal Expansion
Rumaseb A., Moraes Barros RR., Sá JM., Juliano JJ., William T., Braima KA., Barber BE., Anstey NM., Price RN., Grigg MJ., Marfurt J., Auburn S.
Increasing reports of resistance to a frontline malaria blood-stage treatment, chloroquine (CQ), raises concerns for the elimination of Plasmodium vivax . The absence of an effective molecular marker of CQ resistance in P. vivax greatly constrains surveillance of this emerging threat.